IVF (In Vitro Fertilisation): A Complete Guide to Fertility Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

In vitro fertilisation (IVF) is an assisted reproductive technology (ART) in which eggs are retrieved from the ovaries after hormonal stimulation, fertilised with sperm outside the body in an embryology laboratory, and the resulting embryo or embryos are transferred into the uterus to establish pregnancy. Since the birth of Louise Brown in 1978 — the world's first IVF baby — IVF has become the cornerstone of fertility treatment globally, with over 8 million IVF babies born worldwide and approximately 500,000 IVF cycles performed annually in the United States alone.

The IVF process encompasses several distinct phases: ovarian stimulation with injectable gonadotropins (FSH-based medications) over approximately 10–14 days, monitored by serial transvaginal ultrasound and oestradiol blood tests; oocyte retrieval (egg collection) under intravenous sedation via a transvaginal needle guided by ultrasound; fertilisation in the embryology laboratory using standard insemination or intracytoplasmic sperm injection (ICSI — direct injection of a single sperm into the egg); embryo culture for 5–6 days to the blastocyst stage; and embryo transfer into the uterine cavity under ultrasound guidance.

Modern IVF increasingly uses preimplantation genetic testing (PGT-A) to select chromosomally normal euploid embryos before transfer — significantly improving live birth rates per transfer, particularly in patients with recurrent implantation failure or advanced maternal age. Frozen embryo transfer (FET) cycles using frozen-thawed blastocysts from a previous stimulation cycle now account for more than 60% of all transfers at leading IVF centres, with equivalent or superior outcomes to fresh transfers.

IVF is indicated for infertility due to a broad range of aetiologies. Tubal factor infertility (blocked or damaged fallopian tubes — from previous pelvic inflammatory disease, endometriosis, or prior tubal surgery) is an absolute indication for IVF, as sperm cannot reach the egg via natural pathways. Severe male factor infertility — severe oligospermia (low sperm count), asthenospermia (poor sperm motility), or azoospermia requiring surgical sperm retrieval (TESA/PESA/Micro-TESE) — is treated with ICSI. Endometriosis (particularly moderate-to-severe stages III–IV) impairs fertility through multiple mechanisms and is well-treated with IVF.

Ovulatory disorders (polycystic ovary syndrome, premature ovarian insufficiency, hypothalamic amenorrhoea) may be managed with simpler treatments (ovulation induction, IUI) initially but require IVF for definitive treatment in many cases. Unexplained infertility — where standard investigations reveal no identifiable cause — is an indication for IVF after failed intrauterine insemination (IUI) cycles. IVF is also used for fertility preservation (egg or embryo freezing) before chemotherapy, radiotherapy, or gonadotoxic treatments; for single women and same-sex couples using donor sperm; and for women with premature ovarian failure using donor eggs.

IVF candidacy is determined through a comprehensive fertility work-up including: ovarian reserve testing (antral follicle count on transvaginal ultrasound; AMH serum level — anti-Müllerian hormone; basal day 2–3 FSH and oestradiol); uterine assessment by hysteroscopy or sonohysterogram to exclude submucous fibroids, polyps, or intrauterine adhesions; semen analysis (total motile sperm count, morphology); and investigation of tubal status by laparoscopy or hysterosalpingography (HSG). Chromosomal karyotyping for both partners is appropriate with recurrent implantation failure or miscarriage history.

Age is the strongest predictor of IVF outcome — ovarian reserve and egg quality decline progressively after 35, with live birth rates per cycle declining from approximately 40% in women under 35 to 25% at 38–40, 15% at 40–42, and less than 5% above 43 using own eggs. Donor egg IVF restores high success rates for women with poor ovarian reserve or advanced maternal age. Contraindications to IVF using own eggs include absent ovaries, premature ovarian failure without remaining follicles, and uterine anomalies precluding embryo transfer — donor embryos and gestational surrogacy are alternatives in these cases.

IVF protocols are individualised based on patient characteristics, particularly ovarian reserve. Long GnRH agonist protocol (long-down regulation): 2–3 weeks of GnRH agonist (buserelin, leuprorelin) to suppress the pituitary before starting gonadotropin stimulation; historically the standard protocol. GnRH antagonist protocol: stimulation starts from cycle day 2–3; GnRH antagonist (cetrorelix, ganirelix) added from day 5–6 to prevent premature LH surge; shorter, more flexible, preferred for most patients. Mini-IVF/natural cycle IVF: reduced or no gonadotropin stimulation, fewer eggs retrieved, lower drug costs but lower success rates per cycle; appropriate for patients who decline full stimulation or have contra-indications.

Egg retrieval (oocyte pick-up) takes 20–30 minutes under intravenous sedation (propofol-based). Fertilisation: conventional IVF insemination (adding prepared sperm to eggs in the culture dish) for normal semen parameters; ICSI (direct micromanipulation injection of single sperm) for male factor, low fertilisation in previous cycles, or frozen-thawed sperm. Embryo culture to day 5–6 blastocyst stage before either fresh transfer or vitrification (ultra-rapid freezing). Preimplantation genetic testing for aneuploidy (PGT-A) biopsies the trophectoderm cells of each blastocyst for chromosomal screening before transfer, enabling selection of euploid embryos.

Individualised treatment planning is essential to achieve optimal outcomes. Factors including patient age, overall health status, concurrent medications, and personal goals all influence the selection and sequencing of treatment approaches. A specialist consultation — with review of relevant investigations and prior treatment history — is the appropriate first step before any therapeutic intervention is initiated. Patients are encouraged to seek a second opinion for complex or elective procedures to ensure they understand all available options and their respective risks, benefits, and costs.

IVF is the highest-efficacy fertility treatment available. Cumulative live birth rates (taking into account all transfers from one stimulation cycle, including frozen embryo transfers) reach 50–70% in women under 38 per stimulation cycle at experienced IVF centres. In women under 35, fresh embryo transfer success rates of 35–45% per transfer cycle are typical at leading centres. With PGT-A-tested euploid embryo transfer, live birth rates per transfer reach 55–70% in women under 38, independent of age — as chromosomally normal embryos have equivalent implantation rates regardless of maternal age at the time of retrieval.

For patients with tubal factor infertility or severe male factor, IVF with ICSI is the only effective treatment — success rates are determined by egg quality (which is age-related) rather than the infertility diagnosis. Donor egg IVF using a young (21–30 year old) egg donor achieves live birth rates of 50–65% per transfer, independent of the recipient's age — making biological parenthood possible for women in their 40s and early 50s using donor eggs.

Ovarian hyperstimulation syndrome (OHSS) is the most clinically significant complication of IVF stimulation — caused by excessive ovarian response to gonadotropins. Mild OHSS (abdominal bloating, mild discomfort) occurs in 20–33% of cycles; moderate OHSS (significant nausea, vomiting, discomfort, enlarged ovaries) in 3–8%; severe OHSS (ascites, pleural effusion, thromboembolic complications, hospitalisation required) in less than 1% of cycles. Risk is highest in young women with high antral follicle counts and PCOS. GnRH antagonist protocols with GnRH agonist trigger (rather than hCG trigger) have dramatically reduced severe OHSS risk; the 'freeze-all' strategy (no fresh transfer, delayed FET) further mitigates OHSS risk.

Multiple pregnancy is the most important obstetric complication of IVF — associated with prematurity, low birth weight, and maternal complications. Single embryo transfer (SET) policy, increasingly standard at leading centres worldwide, has reduced multiple pregnancy rates from greater than 25% to less than 5% without significantly reducing cumulative live birth rates when frozen embryos are used. Procedural risks of egg retrieval include intra-abdominal bleeding (less than 0.5%), pelvic infection, and rare injury to adjacent structures. Long-term data show no increased risk of ovarian cancer in women who have undergone multiple IVF cycles.

Recovery from egg retrieval is typically rapid — most patients experience mild to moderate pelvic cramping and light vaginal spotting for 24–48 hours and return to normal activities within 1–2 days. Post-retrieval progesterone luteal phase support (vaginal pessaries, subcutaneous injections, or oral micronised progesterone) is prescribed from egg retrieval day until the pregnancy test at 12–14 days post-transfer, and continued to 8–12 weeks gestation if the test is positive.

The serum beta-hCG pregnancy test at 12–14 days post-transfer confirms implantation. A positive result prompts transvaginal ultrasound at 6–7 weeks to confirm intrauterine sac and foetal heartbeat, and the patient is transferred to antenatal care at 8–10 weeks. Singleton IVF pregnancies carry a slightly higher risk of prematurity, low birth weight, and placental complications compared to spontaneous conception — attributed partly to patient factors (maternal age, endometrial receptivity issues) and partly to ART-related mechanisms; first trimester specialist obstetric review is appropriate for all IVF pregnancies. Unexplained IVF failure after 3 cycles with good quality embryos prompts investigation of recurrent implantation failure (endometrial receptivity testing, immunological assessment).

IVF is among the most expensive outpatient medical procedures in high-income countries. In the United States, a single IVF cycle costs USD 12,000–17,000 for the base procedure, with additional costs of USD 3,000–6,000 for ICSI, USD 4,000–8,000 for PGT-A (genetic testing of embryos), and USD 5,000–8,000 per donor egg cycle on top of recipient cycle costs. Most US insurance plans provide limited or no IVF coverage — only 19 states have insurance mandate laws. Average Americans spend USD 25,000–50,000 or more across multiple IVF cycles.

India's IVF sector — with leading fertility centres in Mumbai, Delhi, Bangalore, Hyderabad, Chennai, and Pune — offers complete IVF cycles (ovarian stimulation, egg retrieval, embryology, and embryo transfer) for USD 2,000–4,500. ICSI adds USD 400–800. PGT-A adds USD 1,000–2,500. Donor egg cycles cost USD 3,500–6,000 including donor coordination and recipient preparation. Even accounting for travel, accommodation, and monitoring in the home country, Indian IVF tourism saves patients USD 8,000–15,000 per cycle compared to US prices. Leading Indian fertility centres (Nova IVF Fertility, Cloudnine Fertility, Manipal Fertility, Fortis Bloom IVF) employ ESHRE and ASRM-trained embryologists and maintain laboratory standards comparable to top international centres.

Before proceeding to IVF, less invasive fertility treatments are appropriate for specific indications. Ovulation induction (oral clomiphene citrate or letrozole) is effective for anovulatory infertility (PCOS) without male factor or tubal disease. Intrauterine insemination (IUI) — placing washed prepared sperm directly into the uterus at ovulation — is appropriate for mild male factor, unexplained infertility (up to 3 cycles before IVF), and single women using donor sperm. Success rates per IUI cycle are 8–15% in appropriate patients — lower than IVF but significantly less invasive and expensive.

Laparoscopic surgery for endometriosis, fibroid resection, or tubal reconstructive surgery may restore natural fertility in selected patients before or instead of IVF. In male factor infertility, medical treatment of the underlying cause (varicocele repair, hormonal treatment for hypogonadotropic hypogonadism) may restore sufficient sperm parameters to attempt IUI rather than ICSI-IVF. For couples with no identifiable cause after thorough investigation, expectant management for 6–12 months may result in natural conception, particularly in younger women (under 35) with a shorter duration of infertility.